Glyscend taps CEO to lead oral obe­si­ty, type 2 di­a­betes can­di­date; Ex-Travec­ta chief bounces back af­ter com­pa­ny shut­down

As a new wave of type 2 di­a­betes and obe­si­ty drugs takes the in­dus­try by storm, Glyscend Ther­a­peu­tics has tapped a new CEO to lead …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.